 |
Pharmacokinetics of Insulin
Preparations

|
|
Time of
Action |
|
Preparation |
Onset, h |
Peak, h |
Effective
Duration, h |
|
Short-acting,
subcutaneous |
|
Lispro |
<0.25 |
0.5–1.5 |
3–4 |
|
Aspart |
<0.25 |
0.5–1.5 |
3–4 |
|
Glulisine |
<0.25 |
0.5–1.5 |
3–4 |
|
Regular |
0.5–1.0 |
2–3 |
4–6 |
|
Short-acting,
inhaled |
|
Inhaled
regular insulin |
<0.25 |
0.5–1.5 |
4–6 |
|
Long-acting |
|
NPH |
1–4 |
6–10 |
10–16 |
|
Detemir |
1–4 |
—a |
12–20 |
|
Glargine |
1–4 |
—a |
24 |
|
Insulin
Combinations |
|
75/25–75%
protamine lispro, 25% lispro |
<0.25 |
1.5 hb |
Up to 10–16 |
|
70/30–70%
protamine aspart, 30% aspart |
<0.25 |
1.5 hb |
Up to 10–16 |
|
50/50–50%
protamine lispro, 50% lispro |
<0.25 |
1.5 hb |
Up to 10–16 |
|
70/30–70%
NPH, 30% regular insulin |
0.5–1 |
Dual |
10–16 |
|
50/50–50%
NPH, 50% regular insulin |
0.5–1 |
Dual |
10–16 |
aGlargine
has minimal peak activity; detemir
has some peak activity at 6–14 h.
bDual:
two peaks; one at 2–3 h; the second
several hours later.
References:
-
Hirsch IB. Insulin
analogues.
N Engl J Med. 2005
Jan
13;352(2):174-83.
[Medline]
-
DeWitt DE, Hirsch
IB. Outpatient
insulin therapy in
type 1 and type 2
diabetes mellitus:
scientific review.
JAMA. 2003 May
7;289(17):2254-64.
[Medline]
Created: Dic 31, 2008
Last Modified:
01/22/2010
|
|